Patents by Inventor Stephen S. DOMINY
Stephen S. DOMINY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230142714Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: ApplicationFiled: May 9, 2022Publication date: May 11, 2023Applicant: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Publication number: 20220204457Abstract: Therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A and arginine gingipain B, are disclosed, as well as the use thereof for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, Formula Ia, and Formula Ib, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: March 20, 2020Publication date: June 30, 2022Inventors: Robert A. Galemmo, Andrei W. Konradi, Casey C. Lynch, Stephen S. Dominy
-
Patent number: 11332464Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 4, 2020Date of Patent: May 17, 2022Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 11325884Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: GrantFiled: June 11, 2020Date of Patent: May 10, 2022Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Publication number: 20210355527Abstract: Methods for detecting microbial nucleic acids in a body fluid of a subject are provided. The methods include highly sensitive and specific procedures for detecting DNA derived from the bacteria such as Porphyromonas gingivalis, e.g., using PCR amplification and qPCR detection, in clinical and/or laboratory samples containing CSF or other biofluids.Type: ApplicationFiled: September 27, 2019Publication date: November 18, 2021Applicant: Cortexyme, Inc.Inventors: Debasish Raha, Leslie J. Holsinger, Stephen S. Dominy, Casey C. Lynch
-
Publication number: 20210053908Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: ApplicationFiled: June 11, 2020Publication date: February 25, 2021Applicant: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Patent number: 10906881Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: May 9, 2018Date of Patent: February 2, 2021Assignee: CORTEXYME, INC.Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20210017167Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 4, 2020Publication date: January 21, 2021Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 10730826Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: GrantFiled: March 14, 2019Date of Patent: August 4, 2020Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, Jr., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Patent number: 10676470Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: April 30, 2019Date of Patent: June 9, 2020Assignee: CORTEXYME, INC.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20190322659Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: April 30, 2019Publication date: October 24, 2019Applicant: Cortexyme, Inc.Inventors: Andrei W. Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20190210960Abstract: The present invention provides compounds according to Formula I as described herein, and their use for inhibiting the lysine gingipain protease (Kgp) from the bacterium Porphyromonas gingivalis. Also described are gingipain activity probe compounds and methods for assaying gingipain activity are also described, as well as methods for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease.Type: ApplicationFiled: March 14, 2019Publication date: July 11, 2019Applicant: CORTEXYME, INC.Inventors: Andrei W. Konradi, Robert A. Galemmo, JR., Stephen S. Dominy, Casey C. Lynch, Leslie J. Holsinger
-
Patent number: 10301301Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 4, 2018Date of Patent: May 28, 2019Assignee: CORTEXYME, INC.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20180346460Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: June 4, 2018Publication date: December 6, 2018Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20180334440Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its proteases arginine gingipain A/B (Rgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: May 9, 2018Publication date: November 22, 2018Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey C. Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 9988375Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: August 22, 2017Date of Patent: June 5, 2018Assignee: CORTEXYME, INC.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20170349537Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: August 22, 2017Publication date: December 7, 2017Applicant: Cortexyme, Inc.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Patent number: 9758473Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: GrantFiled: October 5, 2015Date of Patent: September 12, 2017Assignee: CORTEXYME, INC.Inventors: Andrei Konradi, Stephen S. Dominy, Casey Crawford Lynch, Craig Coburn, Joseph Vacca
-
Publication number: 20170014468Abstract: The invention relates to compositions, formulations, vaccines and antibodies for the prevention and/or treatment of aging and brain disorders, including Alzheimer's disease, diabetes, cardiovascular disease, retinal disorders and arthritis. The invention also provides methods of treatment of aging disorders, brain disorders, including Alzheimer's disease, diabetes, cardiovascular disease, retinal disorders, and arthritis by administering compositions, formulations, vaccines and antibodies described in the specification. The invention further provides methods for diagnosing or assessing risk of development of brain disorders in humans and animals. The invention further provides animal models for testing novel therapeutics for brain disorders.Type: ApplicationFiled: April 29, 2015Publication date: January 19, 2017Inventors: Stephen S. Dominy, Casey Crawford Lynch
-
Publication number: 20160096830Abstract: The present invention relates generally to therapeutics targeting the bacterium Porphyromonas gingivalis, including its protease Lysine gingipain (Kgp), and their use for the treatment of disorders associated with P. gingivalis infection, including brain disorders such as Alzheimer's disease. In certain embodiments, the invention provides compounds according to Formula I, as described herein, and pharmaceutically acceptable salts thereof.Type: ApplicationFiled: October 5, 2015Publication date: April 7, 2016Applicant: Cortexyme, Inc.Inventors: Andrei KONRADI, Stephen S. DOMINY, Casey CRAWFORD LYNCH, Craig COBURN, Joseph VACCA